악성 중피종 시장 : 세계 예측(2026-2032년)

The Malignant Mesothelioma Market is projected to grow by USD 1,307.25 million at a CAGR of 8.41% by 2032.

Malignant Mesothelioma Executive Summary

Malignant mesothelioma is an aggressive cancer most often arising in the pleura and strongly associated with prior asbestos exposure, with a long latency period that commonly spans decades. Although asbestos use has been restricted or banned in many jurisdictions, new diagnoses continue because of historical occupational exposure, environmental exposure, and exposure during demolition, shipbreaking, mining, construction, and industrial maintenance. The disease remains clinically challenging due to nonspecific early symptoms, late-stage presentation, complex pathology, and limited long-term survival outcomes.

The malignant mesothelioma landscape is being shaped by earlier diagnostic pathways, multidisciplinary care, biomarker-enabled treatment selection, immunotherapy adoption, and stronger public health surveillance. Key industry-specific priorities include pleural mesothelioma diagnosis, peritoneal mesothelioma management, asbestos-related disease monitoring, thoracic oncology services, clinical trial access, occupational health compliance, and real-world evidence generation. Stakeholders across healthcare delivery, diagnostics, therapeutics, environmental safety, and worker protection are increasingly focused on improving time to diagnosis, expanding access to specialist centers, and aligning treatment decisions with evolving clinical evidence.

Transformative Shifts in the Malignant Mesothelioma Landscape

The malignant mesothelioma landscape is undergoing transformative shifts as care moves from symptom-led diagnosis toward integrated, evidence-based pathways that combine imaging, tissue confirmation, pathology review, molecular testing, and multidisciplinary tumor board assessment. Advances in thoracic oncology have elevated the role of immune checkpoint inhibitors in eligible patients, while chemotherapy, surgery, radiotherapy, and supportive care continue to be used based on disease stage, histology, patient fitness, and specialist evaluation. The distinction between epithelioid, sarcomatoid, and biphasic histology remains critical because histologic subtype is linked to treatment responsiveness and prognosis.

Diagnostic transformation is also accelerating. Immunohistochemistry panels are used to differentiate mesothelioma from metastatic carcinomas, while molecular and cytogenetic markers such as BAP1 loss and CDKN2A deletion can support diagnosis in appropriate clinical contexts. At the same time, occupational and environmental health regulations are influencing disease prevention, with bans or restrictions on asbestos, stricter workplace exposure limits, and remediation protocols. However, legacy asbestos in buildings, industrial assets, and ships remains a persistent risk, making surveillance, safe abatement, and exposure documentation essential components of the broader malignant mesothelioma ecosystem.

Cumulative Impact of Artificial Intelligence on Malignant Mesothelioma

Artificial intelligence is creating a cumulative impact across malignant mesothelioma diagnosis, treatment planning, research, and surveillance. In radiology, AI-enabled image analysis has the potential to support detection of pleural abnormalities, quantify tumor burden, and assist response assessment on computed tomography and other imaging modalities, particularly where disease morphology is diffuse and difficult to measure. In pathology, computational tools can help support digital slide review, pattern recognition, and quality assurance, although expert pathologist confirmation remains essential because mesothelioma diagnosis requires careful integration of morphology, immunophenotype, and clinical context.

AI is also strengthening research and operational decision-making. Natural language processing can extract asbestos exposure histories, symptom patterns, pathology findings, and treatment outcomes from unstructured clinical records, enabling richer real-world evidence. Predictive analytics may support clinical trial matching, risk stratification, and resource planning for thoracic oncology programs. In public health, AI can assist in mapping exposure clusters, prioritizing inspection of aging infrastructure, and linking occupational history data with cancer registry information. The most reliable use cases will depend on validated datasets, transparent algorithms, data privacy safeguards, and clinical governance to reduce bias and avoid overreliance on unverified automated outputs.

Key Regional Insights for Malignant Mesothelioma

In Asia-Pacific, malignant mesothelioma trends are closely tied to heterogeneous asbestos policies, rapid urban redevelopment, legacy industrial exposure, and shipbuilding or shipbreaking activity in parts of the region. Australia and Japan have long-standing recognition of asbestos-related disease, while China, India, South Korea, and Southeast Asian economies face varying levels of diagnostic capacity, occupational surveillance, and remediation readiness. Growth in specialist oncology infrastructure is improving access to imaging, pathology, and systemic treatment, yet underdiagnosis remains a concern where occupational exposure histories are not consistently captured.

Europe has among the strongest policy frameworks, including broad asbestos restrictions across the European Union, but still faces a significant legacy burden due to historical industrial use. The United Kingdom, Germany, France, Italy, and Spain continue to manage cases linked to occupational exposure decades earlier, with specialized thoracic oncology and pathology capabilities supporting evidence-based care. Renovation of older buildings, energy-efficiency upgrades, and infrastructure redevelopment reinforce the need for asbestos surveys, certified abatement, and worker protection protocols.

North America has a mature malignant mesothelioma care environment supported by cancer registries, occupational safety rules, specialist thoracic oncology programs, and litigation-driven exposure documentation. The United States and Canada have extensive experience managing asbestos-related disease due to historical use in construction, manufacturing, shipyards, and military facilities. Clinical trial networks, immunotherapy adoption, and integrated palliative care are key strengths, while ongoing risk stems from older buildings and industrial sites containing asbestos materials.

Latin America presents a mixed picture, with Brazil and Mexico serving as important anchors for oncology services while regional access to specialist diagnostics and treatment remains uneven. Differences in asbestos regulation, worker protections, cancer registry completeness, and access to expert pathology influence disease identification and care continuity. Strengthening occupational medicine links with oncology referral pathways is central to improving malignant mesothelioma recognition across the region.

Africa faces substantial challenges, including limited diagnostic infrastructure, underreporting, variable asbestos regulation, and historical mining or industrial exposure in specific countries. Across African health systems, strengthening cancer registries, occupational health surveillance, pathology capacity, and safe asbestos abatement practices is central to improving malignant mesothelioma recognition and outcomes.

The Middle East shows rising relevance due to construction activity, industrial expansion, and reliance on migrant labor in certain markets, making occupational safety enforcement and asbestos management essential. GCC countries are investing in advanced healthcare infrastructure, which can support earlier diagnosis and access to oncology care when referral systems are well coordinated.

Key Group Insights for Malignant Mesothelioma

NATO member countries share overlapping concerns related to asbestos in military ships, bases, older facilities, and veteran exposure histories, making defense-related surveillance, remediation, exposure documentation, and healthcare access important elements of malignant mesothelioma policy and care. Coordinated approaches to facility inspection, veteran health monitoring, and safe maintenance of aging defense infrastructure can help reduce preventable exposure and support timely diagnosis.

The G7 has more established cancer care systems, broader access to immunotherapy and clinical trials, and stronger occupational health frameworks, but continues to carry a legacy asbestos burden in public buildings, homes, ships, and industrial assets. Across these high-income health systems, the key priority is integrating early referral, specialist pathology review, multidisciplinary thoracic oncology, and palliative care while maintaining rigorous asbestos control during renovation and demolition.

BRICS countries show diverse malignant mesothelioma dynamics, reflecting differences in asbestos production history, industrialization, regulatory maturity, and oncology infrastructure. Brazil, Russia, India, China, and South Africa each require stronger integration of occupational exposure records, cancer registry data, and specialist diagnostic services to support accurate disease recognition, particularly where asbestos exposure histories may be incomplete or underreported.

In the European Union, comprehensive asbestos restrictions, workplace safety directives, and cancer control initiatives provide a strong policy environment, yet the long latency of mesothelioma means cases continue to emerge from past exposures. The EU's focus on building renovation and energy efficiency also increases the importance of safe asbestos surveys, certified abatement, and workforce protection before redevelopment.

Within ASEAN, malignant mesothelioma priorities are shaped by industrial growth, construction activity, uneven asbestos regulation, and variable access to specialist cancer diagnostics. Countries with expanding urban infrastructure face increased need for asbestos identification, demolition controls, worker training, occupational disease surveillance, pathology networks, and exposure history documentation to reduce underdiagnosis across the group.

The GCC is characterized by substantial healthcare investment and ongoing construction and infrastructure development, which makes asbestos risk management and worker protection central to long-term disease prevention. Coordinated inspection programs, migrant worker health surveillance, and referral pathways to thoracic oncology specialists can improve malignant mesothelioma detection and management.

Key Country Insights for Malignant Mesothelioma

China's malignant mesothelioma landscape is shaped by large-scale industrial activity, urban redevelopment, and the need for stronger occupational exposure capture and specialist diagnostic standardization. The United States has a well-developed malignant mesothelioma care environment supported by specialist cancer centers, clinical trials, asbestos exposure documentation, and occupational safety oversight, though legacy asbestos in older buildings, shipyards, industrial sites, and military assets remains relevant. Japan has established recognition of asbestos-related disease and advanced oncology services, while continued monitoring is needed for historically exposed populations. India faces notable challenges related to asbestos use in building materials, worker protection, and access to pathology-confirmed diagnosis, particularly outside major cities.

Germany, the United Kingdom, France, Italy, and Spain continue to address legacy exposure through occupational health systems, pathology expertise, cancer registry infrastructure, and thoracic oncology services, while renovation of older buildings requires rigorous asbestos control. The United Kingdom has extensive experience with asbestos-related disease due to historical industrial and construction exposure, supported by specialist mesothelioma services. Germany and France benefit from structured occupational health frameworks and advanced oncology systems, while Italy and Spain continue to manage cases linked to historical industrial, construction, and shipyard exposure.

Australia has one of the most visible asbestos disease burdens globally due to past high asbestos use, with strong public awareness, compensation systems, and specialist care infrastructure. South Korea has strengthened asbestos controls and healthcare capacity, with ongoing importance placed on environmental exposure management, worker surveillance, and early referral. Canada has implemented strong asbestos restrictions and maintains public health attention on exposure prevention, while ongoing cases reflect past use in construction and mining-linked industries. Russia's profile is influenced by industrial history and the need for consistent exposure surveillance, cancer registration, and specialist access across a large geography.

Brazil has important oncology capacity in major urban centers, but regional disparities in diagnosis and treatment access influence malignant mesothelioma care pathways. Mexico faces the dual challenge of improving occupational surveillance and expanding timely access to specialist pathology and oncology services. Across all priority countries, consistent tissue diagnosis, accurate histologic classification, validated immunohistochemistry, appropriate molecular testing, and access to multidisciplinary care are decisive factors in improving malignant mesothelioma outcomes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize earlier diagnosis by strengthening referral pathways from primary care, pulmonology, occupational medicine, and emergency departments to specialist thoracic oncology teams. Standardized diagnostic protocols should include detailed occupational and environmental exposure histories, high-quality imaging, expert pathology review, immunohistochemistry, and appropriate molecular testing to improve diagnostic confidence and treatment planning.

Healthcare systems and service providers should expand multidisciplinary mesothelioma programs that integrate medical oncology, thoracic surgery, radiation oncology, pathology, radiology, pulmonology, palliative care, rehabilitation, and psychosocial support. Diagnostics stakeholders should invest in validated digital pathology, AI-assisted image analysis, and real-world evidence platforms while maintaining clinical oversight and regulatory compliance. Public and private sector decision-makers should accelerate asbestos mapping, safe abatement, worker education, and exposure surveillance, especially in older buildings, shipyards, industrial facilities, mines, and redevelopment projects. Research leaders should improve clinical trial access, include underrepresented populations, and develop biomarker-driven strategies to support more personalized malignant mesothelioma treatment.

Research Methodology

This executive summary is based on a structured secondary research methodology using publicly available, verifiable sources such as cancer registry publications, occupational health guidance, peer-reviewed medical literature, clinical practice guidelines, government asbestos regulations, public health agency materials, and international cancer and labor health resources. Evidence was prioritized when it reflected established clinical consensus, documented asbestos exposure pathways, validated diagnostic practices, recognized treatment standards, or region-specific regulatory and healthcare infrastructure factors.

The research approach included cross-comparison of epidemiological patterns, asbestos policy environments, diagnostic standards, treatment pathway developments, and regional healthcare capacity. Insights were synthesized qualitatively to avoid unsupported quantification and to maintain compliance with the exclusion of market estimation, market sizing, market share, and forecasting. Particular emphasis was placed on malignant pleural mesothelioma, asbestos-related disease surveillance, pathology confirmation, multidisciplinary care, immunotherapy integration, artificial intelligence applications, and occupational exposure prevention.

Conclusion

Malignant mesothelioma remains a high-need oncology and occupational health challenge driven by long-latency asbestos exposure, diagnostic complexity, and aggressive disease biology. While regulatory action has reduced new asbestos use in many regions, the global burden persists because of legacy materials, uneven enforcement, and gaps in surveillance. Advances in immunotherapy, pathology, imaging, real-world evidence, and AI-enabled workflows are improving the ability to detect, classify, and manage the disease, but patient outcomes continue to depend heavily on early referral and access to experienced multidisciplinary teams.

The most effective strategic response combines clinical innovation with prevention-focused public health action. Stakeholders that invest in asbestos exposure control, specialist diagnostic capacity, equitable treatment access, validated digital tools, and robust occupational surveillance will be better positioned to address the continuing impact of malignant mesothelioma across mature and emerging healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Malignant Mesothelioma Market, by Disease Type

• 7.1. Introduction
• 7.2. Pleural Mesothelioma
• 7.3. Peritoneal Mesothelioma
• 7.4. Pericardial Mesothelioma
• 7.5. Tunica Vaginalis Mesothelioma

8. Malignant Mesothelioma Market, by Treatment Type

• 8.1. Introduction
• 8.2. Chemotherapy
• 8.3. Immunotherapy
• 8.4. Targeted Therapy
• 8.5. Cell Therapy
• 8.6. Gene Therapy
• 8.7. Tumor Treating Fields
• 8.8. Radiation Therapy

9. Malignant Mesothelioma Market, by Drug Class

• 9.1. Introduction
• 9.2. Antifolate Agents
• 9.3. Platinum-Based Agents
• 9.4. Immune Checkpoint Inhibitors
• 9.5. Monoclonal Antibodies
• 9.6. Cell & Gene Therapies

10. Malignant Mesothelioma Market, by Line of Therapy

• 10.1. Introduction
• 10.2. First-Line Treatment
• 10.3. Second-Line Treatment
• 10.4. Third-Line and Later Therapy

11. Malignant Mesothelioma Market, by End User

• 11.1. Introduction
• 11.2. Hospitals
• 11.3. Cancer Centers
• 11.4. Specialty Oncology Clinics
• 11.5. Academic Medical Centers
• 11.6. Research Institutes

12. Malignant Mesothelioma Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Malignant Mesothelioma Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Malignant Mesothelioma Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Amgen Inc.
• 16.2. AstraZeneca PLC
• 16.3. Atara Biotherapeutics, Inc.
• 16.4. Bayer AG
• 16.5. Boehringer Ingelheim International GmbH
• 16.6. Bristol-Myers Squibb Company
• 16.7. Candel Therapeutics, Inc.
• 16.8. Cartesian Therapeutics, Inc.
• 16.9. Eli Lilly and Company
• 16.10. F. Hoffmann-La Roche AG
• 16.11. GSK plc
• 16.12. Merck & Co., Inc.
• 16.13. Novocure Ltd.
• 16.14. Pfizer Inc.
• 16.15. SELLAS Life Sciences Group, Inc.
• 16.16. Sensei Biotherapeutics, Inc.
• 16.17. Takeda Pharmaceutical Company Limited